Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477757 | 1.00 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL14816525 | 0.92 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL30316100 | 0.90 | LPL (0.39) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL25832767 | 0.90 | LPL (0.39) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL1646761 | 0.90 | LPL (0.44) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL26153576 | 0.86 | LPL (0.39) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL25395984 | 0.86 | LPL (0.41) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL24457822 | 0.84 | CYP3A4 (0.35) | LPLLIPGJAK2BTKMAPK1 | |
| SCHEMBL30935317 | 0.84 | CYP3A4 (0.35) | LPLLIPGJAK2BTKMAPK1 | |
| SCHEMBL24839990 | 0.84 | JAK2 (0.36) | LPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334295-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuoscience, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |